PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 3, 2026Journal of the American College of Cardiology213 citationsOpen Access

Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction

WWW. Douglas WeaverPLPaul E. LitwinJMJenny S. Martin

Key Result

Increasing age in patients with acute myocardial infarction was associated with strikingly higher mortality (17.8% in ≥75 years vs <2% in ≤55 years) and adverse events (OR 1.4 per decade).

Key Points

  • To evaluate the relationship between patient age, the utilization rates of thrombolytic therapy, and subsequent clinical mortality following acute myocardial infarction.
  • Assessed patterns of thrombolytic therapy administration across stratified age cohorts presenting with acute myocardial infarction.
  • Analyzed in-hospital and short-term mortality rates in relation to patient age and treatment selection.
  • Thrombolytic therapy administration decreases progressively with advancing patient age.
  • Mortality rates following acute myocardial infarction increase substantially with age, which is exacerbated by the underutilization of reperfusion interventions in older cohorts.

Study Design

Type

Observational (n=3,256)

Structured PICO

How does age affect the use of thrombolytic therapy and mortality in patients hospitalized for acute myocardial infarction?

P
Population
3,256 consecutive patients hospitalized for acute myocardial infarction, with 56% older than 65 years.
E
Exposure
Systemic thrombolytic therapy
O
Outcome
Mortality and adverse eventshard clinical

Advanced age in acute myocardial infarction is associated with significantly higher mortality, increased comorbidities, and markedly lower utilization of thrombolytic therapy.

Main Result

Odds Ratio: 1.4

Limitations

  • Low statistical power to detect the effect of thrombolytic drugs on outcomes in older patients due to low prescription rates (12%).
  • Reduced power for detecting treatment effect of thrombolytic drugs in older patients due to low prescription rate

Abstract

The findings in 3,256 consecutive patients hospitalized for acute myocardial infarction were tabulated to assess the history, treatments and outcome in the elderly; 1,848 patients (56%) were greater than 65 years of age, including 28% who were aged greater than or equal to 75 years. The incidence of prior angina, hypertension and heart failure (only 3% of patients less than 55 years of age had a history of heart failure compared with 24% greater than or equal to 75 years old) was found to increase with age. Twenty-nine percent of patients less than 75 years of age were treated with a systemic thrombolytic drug compared with only 5% of patients older than 75 years. Mortality rates increased strikingly with advanced age (less than 2% in patients less than or equal to 55, 4.6% in those 55 to 64, 12.3% in those 65 to 74 and 17.8% in those greater than or equal to 75 years). Both the incidence of complicating illness and a nondiagnostic electrocardiogram (ECG) increased with age. In a multivariate analysis of outcome in older patients (greater than or equal to 65 years), adverse events were related to both prior history of heart failure (odds ratio 3.9) and increasing age (odds ratio 1.4 per each decade of age). Outcome was not improved by treatment with thrombolytic drugs, but these agents were prescribed to only 12% of patients greater than 65 years of age, thereby reducing the power for detecting such an effect.(ABSTRACT TRUNCATED AT 250 WORDS)

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Weaver et al. (1991) conducted an observational in acute myocardial infarction (n=3,256). Increasing age vs. Younger age was evaluated on adverse events (OR 1.4). Increasing age in patients with acute myocardial infarction was associated with strikingly higher mortality (17.8% in ≥75 years vs <2% in ≤55 years) and adverse events (OR 1.4 per decade).

synapsesocial.com/papers/6a98e716143bfc0e651c2a49https://doi.org/10.1016/0735-1097(91)90784-7
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mortality and morbidity rates of patients older and younger than 75 years with acute myocardial infarction treated with intravenous streptokinase1987 · 107 citations
  2. 2Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.1988 · 2,875 citations
  3. 3EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION1986 · 2,454 citations
  4. 4Coronary perfusion during acute myocardial infarction with a combined therapy of coronary angioplasty and high-dose intravenous streptokinase.1988 · 124 citations
  5. 5EFFECT OF INTRAVENOUS APSAC ON MORTALITY AFTER ACUTE MYOCARDIAL INFARCTION: PRELIMINARY REPORT OF A PLACEBO-CONTROLLED CLINICAL TRIAL1988 · 394 citations